However, the activity of EGFR inhibitors alone is relatively modest and limited to a minority of patients, and in the absence of a reliable predictive biomarker of response, it is unclear how to identify HNSCC patients most likely to benefit from EGFR-targeted agents [18,19]. The gene discussed is EGFR; the disease is head and neck squamous cell carcinoma.